Literature DB >> 27805464

A Review of the Course and Treatment of Non-Infectious Uveitis during Pregnancy.

Lindsay A Grotting1, George N Papaliodis1.   

Abstract

Inflammatory conditions such as autoimmune uveitis often occur in women of childbearing age. During pregnancy, women may experience exacerbations of their disease in the first trimester. In the later stages of pregnancy, however, the uveitis tends to remain less active. The management of uveitis during pregnancy is a challenging task, forcing the physician to re-evaluate the patient's current therapy and offer alternative options that pose the least risk to the patient and fetus. This article will review treatments widely used for uveitis, including corticosteroid therapy, anti-metabolites, calcineurin inhibitors, and biologic therapy. It will evaluate the use of these medications in pregnancy and the postpartum state.

Entities:  

Keywords:  Autoimmune disease; biologics; lactation; ocular inflammatory disease

Mesh:

Substances:

Year:  2016        PMID: 27805464     DOI: 10.1080/08820538.2016.1228402

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  3 in total

1.  The effect of pregnancy on the course of uveitis in single and multiple pregnancies.

Authors:  Yael Sharon; Avital Adler; Alon Tiosano; Juan M Sanchez; Radgonde Amer; Michal Kramer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-09-12       Impact factor: 3.535

2.  Idiopathic multifocal choroiditis and punctate inner choroidopathy: an evaluation in pregnancy.

Authors:  Evianne L de Groot; Ramon A C van Huet; Kitty W M Bloemenkamp; Joke H de Boer; Jeannette Ossewaarde-van Norel
Journal:  Acta Ophthalmol       Date:  2021-05-19       Impact factor: 3.988

3.  Pregnancy-Induced Changes in microRNA Expression in Multiple Sclerosis.

Authors:  Helle Bach Søndergaard; Laura Airas; Jeppe Romme Christensen; Birgitte Romme Nielsen; Lars Börnsen; Annette Oturai; Finn Sellebjerg
Journal:  Front Immunol       Date:  2021-01-28       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.